Morgan Stanley
-
-
-
-
-
-
-
Biogen (BIIB) gains as analysts reflect positively on Leqembi's approval, pricing
-
-
-
-
-
-
-
Morgan Stanley Sees 90% Probability of Biogen (BIIB) Moving 10%+ Higher Upon Receiving Alzheimer's Disease NCD Draft Coverage
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $352 at Morgan Stanley
-
-
-
-
-
-
-
Pre-Open Stock Movers 02/18: (LM) (BEN) (AAP) Higher; (FLR) (CAG) (CVU) Lower (more...)
-
-
-
-
-
-
-
Biogen (BIIB) PT Raised to $369 at Morgan Stanley
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $301 at Morgan Stanley
-
-
-
-
-
-
-
Morgan Stanley Downgrades Biogen (BIIB) to Equalweight
-
224,861 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

